EPS for Axovant Sciences Ltd. (AXON) Expected At $-0.39 on June, 12

May 17, 2018 - By Amber Marburger

Axovant Sciences Ltd. (NASDAQ:AXON) Corporate Logo

On June, 12 Axovant Sciences Ltd. (NASDAQ:AXON)’s earnings report is expected by WallStreet, Faxor reports. This year’s EPS analyst estimate is expected to be $-0.39. That is 26.42 % up compareed to $-0.53 EPS for last year. The stock increased 5.98% or $0.07 during the last trading session, hitting $1.24.Axovant Sciences Ltd. has volume of 448,778 shares. Since May 17, 2017 AXON has declined 90.77% and is downtrending. The stock underperformed the S&P 500 by 102.32%.

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe.The company has $133.66 million market cap. The Company’s lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of Alzheimer??s disease; in Phase IIb clinical trial for treating dementia with Lewy bodies ; and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia.Last it reported negative earnings. The firm is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM behavior disorder in patients with LBD.

Axovant Sciences Ltd. (NASDAQ:AXON) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.